Alfadil Haroon: New Genetic Insights into Bone Marrow Failure Syndromes
Alfadil Haroon, Assistant Consultant of Hematology at King Faisal Specialist Hospital and Research Centre, Assistant Professor at Alfaisal University, shared a post on LinkedIn:
“Happy to share our book chapter titled ‘Newly Recognized Marrow Failure Syndromes‘ in the textbook on bone marrow failure syndromes.
This chapter reviews recently identified bone marrow failure syndromes described between 2012 and 2025, expanding beyond the classical conditions such as Fanconi anemia and Dyskeratosis congenita.
Advances in Next-Generation Sequencing have enabled the discovery of several novel genetic etiologies, including MYSM1, DNAJC21, ADH5/ALDH2, MECOM, ERCC6L2,TP53,OSM, and SAMD9/SAMD9L.
These findings are reshaping our understanding of inherited BMF, highlighting diverse clinical phenotypes, early onset cytopenias, and variable risks of progression to myeloid malignancies.
Improved genomic insights are helping clinicians refine diagnosis, risk assessment, and treatment strategies.”
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities
-
Apr 22, 2026, 14:10Alan Nurden: Pregnancy Challenges and Bleeding Risks in Inherited Platelet Disorders
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing
-
Apr 22, 2026, 11:47We Are Excited to Introduce You to the 11th Editor-in-Chief Dr. Bob Löwenberg – Blood Journals Portfolio
-
Apr 22, 2026, 11:35Congratulations to Donald Arnold for Being Recognized with The ISTH 2026 Harold R. Roberts Award
-
Apr 22, 2026, 11:27Prashasti Dahiya: Key Molecular Insights on Thromboinflammation and Angiogenesis in Pediatric Cancer
-
Apr 22, 2026, 11:17Jack Hadfield: Understanding the Immune and Genetic Basis of VITT Post-COVID Vaccines